Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gliclazide
Drug ID BADD_D01022
Description Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It has been classified differently according to its drug properties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one aromatic group.[A39546] On the other hand, based on the pharmacological efficacy, gliclazide is considered a second-generation sulfonylurea which presents a higher potency and a shorter half-life.[T238, T360] Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%).
Indications and Usage For the treatment of NIDDM in conjunction with diet and exercise.
Marketing Status Not Available
ATC Code A10BB09
DrugBank ID DB01120
KEGG ID D01599
MeSH ID D005907
PubChem ID 3475
TTD Drug ID D0M2MR
NDC Product Code 58793-014
Synonyms Gliclazide | Glyclazide | Gliklazid | Diamicron | S-1702 | S 1702 | S1702 | S-852 | S 852 | S852 | Diaglyk | Gen-Gliclazide | Gen Gliclazide | Glyade | Novo-Gliclazide | Novo Gliclazide | Diaikron | Diabrezide
Chemical Information
Molecular Formula C15H21N3O3S
CAS Registry Number 21187-98-4
SMILES CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal discomfort15.03.04.001--Not Available
Cerebrovascular insufficiency24.04.06.004; 17.08.02.003--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Benign gastrointestinal neoplasm07.20.01.001; 16.05.01.001--Not Available
Lipid metabolism disorder14.08.04.003--Not Available
Malnutrition14.03.02.004--Not Available
Mental disorder19.07.01.002--Not Available
Porphyrin metabolism disorder14.14.01.006; 09.01.10.004; 03.08.01.006--Not Available
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049--Not Available
Lacrimal disorder06.08.02.005--Not Available
Blood disorder01.05.01.004--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.001--
Renal impairment20.01.03.010--Not Available
Respiratory tract infection11.01.08.017; 22.07.07.001--Not Available
Cystitis noninfective20.03.02.001--
Acute kidney injury20.01.03.016--
Anal incontinence17.05.01.021; 07.01.06.029--
The 8th Page    First    Pre   8    Total 8 Pages